SEC Form 4	
------------	--

П

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Check this box if no longer subject to
Section 16. Form 4 or Form 5
obligations may continue. See
Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL									
OMB Number:	3235-0287								
Estimated average bu	ırden								

hours per response:	0.5
Estimated average burden	

1. Name and Address of Reporting Person* Dorsch Marion (Last) (First) (Middle) C/O BLUEPRINT MEDICINES CORPORATION 45 SIDNEY STREET		rson*	2. Issuer Name and Ticker or Trading Symbol <u>Blueprint Medicines Corp</u> [BPMC]		ationship of Reporting Pe (all applicable) Director	10% Owner
			3. Date of Earliest Transaction (Month/Day/Year) 09/17/2018	- X	Officer (give title below) Chief Scientifi	Other (specify below) c Officer
(Street) CAMBRIDGE (City)	MA (State)	02139 (Zip)	4. If Amendment, Date of Original Filed (Month/Day/Year)	6. Indiv Line) X	vidual or Joint/Group Fili Form filed by One Re Form filed by More th Person	porting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transa Code (8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	v	Amount	(A) or (D)	Price	Transaction(s) (Instr. 3 and 4)		(1150. 4)
Common Stock	09/17/2018		M ⁽¹⁾		2,300	A	\$37.11	2,300	D	
Common Stock	09/17/2018		S ⁽¹⁾		300	D	\$73.05 ⁽²⁾	2,000	D	
Common Stock	09/17/2018		S ⁽¹⁾		300	D	\$70.59 ⁽³⁾	1,700	D	
Common Stock	09/17/2018		S ⁽¹⁾		1,700	D	\$70	0	D	

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

	(0.5., parts, cano, opinions, control and coordinately														
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transa Code (8)		of		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Stock Option (Right to Buy)	\$37.11	09/17/2018		M ⁽¹⁾			2,300	(4)	11/21/2026	Common Stock	2,300	\$0	116,900	D	

Explanation of Responses:

1. Effected pursuant to a trading plan adopted on December 18, 2017 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended.

2. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$72.89 to \$73.36 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) and (3) to this Form 4.

3. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$70.30 to \$71.06 per share.

4. This option was granted on November 21, 2016. This option vested with respect to 25% of the shares underlying the option on November 21, 2017 and vests as to an additional 1/48th of the shares underlying the option each month thereafter.

<u>/s/ Christopher Frankenfield,</u> <u>Attorney-in-Fact</u>

09/19/2018

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.